Ipamorelin
A selective ghrelin mimetic studied in laboratory settings for selective growth hormone secretion
About Ipamorelin
Ipamorelin (CAS 170851-70-4) is a selective growth hormone secretagogue developed for its targeted ghrelin receptor activation, with preclinical studies noting minimal cross-reactivity with cortisol and prolactin pathways—a selectivity profile that has made it one of the most widely used GHRPs in growth hormone research.
Ipamorelin was developed by scientists at Novo Nordisk in Denmark during the late 1990s. At the time, researchers were looking for better ways to stimulate growth hormone release without the side effects that came with earlier compounds. The existing peptides like GHRP-6 worked, but they also raised cortisol levels and stimulated appetite—effects that weren't always wanted.
The Novo Nordisk team created Ipamorelin specifically to avoid these problems. They designed it to be highly selective, targeting the ghrelin receptor in a way that triggered growth hormone release without significantly affecting other hormones. When they tested it, the results were encouraging—strong GH release with minimal impact on cortisol or prolactin.
This selectivity made Ipamorelin stand out from other growth hormone releasing peptides. Labs began using it when they wanted clean GH stimulation for research without the confounding effects of hormonal changes elsewhere in the body. Today, it remains one of the most popular peptides for growth hormone pathway research.
Quick Facts
| CAS Number | 170851-70-4 |
|---|---|
| Molecular Formula | C₃₈H₄₉N₉O₅ |
| Molar Mass | 711.9 g/mol |
| Sequence | 5 amino acids (pentapeptide) |
| Form | Lyophilized powder |
| Purity | 99%+ (HPLC verified) |
| Third-Party Testing | Freedom Diagnostics (COA included) |
| Storage | Room temp 3–4 months; refrigerate post-reconstitution |
| Price (from) | $60.00 USD |
| SKU | PF-IPAM-10MG |
How Ipamorelin Works
Ipamorelin selectively activates ghrelin receptors to stimulate growth hormone release without affecting cortisol, prolactin, or other hormones. This clean mechanism makes it one of the most selective GHRPs for research applications.
Selective GHS-R1a Binding
Ipamorelin binds to ghrelin receptors with high selectivity, producing GH release without stimulating ACTH (which would raise cortisol) or affecting prolactin levels. This selectivity is unique among GHRPs studied in preclinical and clinical research.
Pulsatile GH Release
Ipamorelin produces dose-dependent, pulsatile GH secretion that mimics natural physiological patterns. Peak GH levels occur 30-60 minutes post-administration and return to baseline within 2-3 hours in clinical pharmacokinetic studies.
Favorable Safety Profile
Unlike GHRP-2 and GHRP-6, ipamorelin does not significantly stimulate appetite or cause cortisol spikes in preclinical studies. This clean pharmacological profile has made it well-suited for GH-axis research applications.
Frequently Asked Questions
- What is Ipamorelin?
- Ipamorelin (CAS 170851-70-4) is a selective growth hormone secretagogue developed for its targeted ghrelin receptor activation, with preclinical studies noting minimal cross-reactivity with cortisol and prolactin pathways—a selectivity profile that has made it one of the most widely used GHRPs in growth hormone research.
- What is the CAS number for Ipamorelin?
- The CAS number for Ipamorelin is 170851-70-4.
- What purity is Peptide Foundry's Ipamorelin?
- Peptide Foundry's research peptides are manufactured to 99%+ purity. Every batch is verified by an independent third-party laboratory (Freedom Diagnostics) using high-performance liquid chromatography (HPLC) for purity and identity, Limulus amebocyte lysate (LAL) assay for bacterial endotoxin, and inductively coupled plasma mass spectrometry (ICP-MS) for heavy-metal contamination. A Certificate of Analysis is published for every product and batch.
- How should Ipamorelin be stored?
- Lyophilized (freeze-dried) peptides are stable at room temperature for 3–4 months. Once reconstituted with bacteriostatic water, store refrigerated (2–8 °C) and use within 30 days. Keep away from direct light and extreme temperatures.
- Does Ipamorelin ship with a Certificate of Analysis?
- Yes. Every batch of every product ships with a Certificate of Analysis from Freedom Diagnostics, an independent third-party analytical laboratory. The COA documents HPLC purity, peptide identity, endotoxin testing, and heavy-metals screening.
- Is Ipamorelin sold for human use?
- No. All products sold by Peptide Foundry are strictly for in-vitro research and laboratory use only (RUO). They are not intended for human or animal consumption, therapeutic use, or diagnostic application.
Scientific References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998. PubMed: 9849822
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide. Pharmaceutical Research. 1999. PubMed: 10496658
- Svensson J, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology. 2000. PubMed: 10828840
- Ghigo E, et al. Growth hormone secretagogues: clinical applications. Journal of Endocrinological Investigation. 1997.
This product is sold strictly for in-vitro research use only (RUO). It is not intended for human or animal consumption, therapeutic use, or diagnostic application.